1921
Volume 85, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Because 8-aminoquinolines affect critical survival stages of parasites, treatment and control of malaria could be markedly improved by more widespread use of these drugs; however, hemolytic toxicity, which is widely prevalent in G6PD-deficient patients, severely constrains this use. Primaquine was approved more than 50 years ago after extensive clinical testing. Review of the mid-20th century literature in the light of present understanding of pharmacokinetics and metabolism suggests that manipulation of these factors might dissociate 8-aminoquinoline efficacy from toxicity and lead to an improved therapeutic index.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.2011.11-0498
2011-12-01
2020-07-05
Loading full text...

Full text loading...

/deliver/fulltext/14761645/85/6/1010.html?itemId=/content/journals/10.4269/ajtmh.2011.11-0498&mimeType=html&fmt=ahah

References

  1. Baird JK, Fryauff DJ, Basri H, Bangs MJ, Subianto B, Wiady I, Purnomo, Leksana B, Masbar S, Richie TL, Jones TR, Tjitra E, Wignall ES, Hoffman SL, 1995. Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. Am J Trop Med Hyg 52: 479484.
    [Google Scholar]
  2. World Health Organization, 2006. Guidelines for the Treatment of Malaria, 2nd ed. Geneva, Switzerland: World Health Organization, 5258.
    [Google Scholar]
  3. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo AP, Naing AL, Nyo MY, Myint NZ, Imwong M, Ashley E, Lee SJ, White NJ, 2010. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 10: 673681.[Crossref]
    [Google Scholar]
  4. Douglas NM, Nosten F, Ashley EA, Phaiphun L, van Vugt M, Singhasivanon P, White NJ, Price RN, 2011. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis 52: 612620.[Crossref]
    [Google Scholar]
  5. Beutler E, Duparc S, 2007. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg 77: 779789.
    [Google Scholar]
  6. WHO Working Group, 1989. G6PD deficiency. Bull World Health Organ 67: 601611.
    [Google Scholar]
  7. Brueckner RP, Ohrt C, Baird JK, Milhous W, 2001. 8-aminoquinolines. Rosenthal PJ, ed. Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery. Totowa, NJ: Humana Press Inc.
    [Google Scholar]
  8. Lysenko AV, 1960. Use of quinocide in treatment and prophylaxis of vivax malaria. Bull World Health Organ 22: 641662.
    [Google Scholar]
  9. Alving AS, 1954. Clinical treatment of malaria. Recent Adv Med Surg 2: 209218.
    [Google Scholar]
  10. Alving AS, Craige B, Jones R, Whorton CM, Pullman TN, Eichelberger L, 1948. Pentaquine (Sn-13,276), a therapeutic agent effective in reducing the relapse rate in vivax malaria. J Clin Invest 27: 2533.[Crossref]
    [Google Scholar]
  11. Craige B, Jones R, Whorton CM, Pullman TN, Alving AS, Eichelberger L, 1947. Clinical standardization of pamaquine (plasmochin) in mosquito-induced vivax malaria, Chesson strain. Am J Trop Med 27: 309315.
    [Google Scholar]
  12. Alving AS, Arnold J, Hockwald RS, Clayman CB, Dern RJ, Beutler E, Cl Flanagan, 1955. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med 46: 301306.
    [Google Scholar]
  13. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ, 2006. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 75: 402415.
    [Google Scholar]
  14. Earle DP, Bigelow FS, Zubrod CG, Kane CA, 1948. Studies on the chemotherapy of the human malarias. IX. Effect of pamaquine on the blood cells of man. J Clin Invest 27: 121129.[Crossref]
    [Google Scholar]
  15. Atchley JA, Yount EH, 1948. Reactions observed during treatment with pentaquine, administered with quinacrine (atabrine) metachloridine (sn-11,437) and with sulfadiazine. J Natl Malar Soc 7: 118124.
    [Google Scholar]
  16. Clayman CB, Arnold J, Hockwald RS, Yount EH, Edgcomb JH, Alving A, 1952. Toxicity of primaquine in caucasians. J Am Med Assoc 149: 15631568.[Crossref]
    [Google Scholar]
  17. Craige B, Eichelberger L, Jones R, Alving AS, Pullman TN, Whorton CM, 1948. The toxicity of large doses of pentaquine (sn-13,276), a new antimalarial drug. J Clin Invest 27: 1724.[Crossref]
    [Google Scholar]
  18. Zubrod CG, Kennedy TJ, Shannon J, 1948. Studies on the chemotherapy of the human malarias; the physiological disposition of pamaquine. J Clin Invest 27: 114120.[Crossref]
    [Google Scholar]
  19. Armer RE, Barlow JS, Dutton CJ, Greenway D, Greenwood S, Lad N, Thompson AP, Thong K, Tommasini I, 1998. 8-aminoquinolines as anticoccidials—II. Bioorg Med Chem Lett 8: 14871492.[Crossref]
    [Google Scholar]
  20. Bates MB, Meshnick SR, Sigler CI, Leland P, Hollingdale MR, 1990. In vitro effects of primaquine and primaquine metabolites on exoerythrocytic stages of Plasmodium berghei . Am J Trop Med Hyg 42: 532537.
    [Google Scholar]
  21. Li XQ, Anders Bjorkman AE, Andersson TB, Gustafsson LL, Collen AE, Masimirembwa M, 2003. Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 59: 429442.[Crossref]
    [Google Scholar]
  22. Cuong BT, Binh VQ, Dai B, Duy DN, Lovell CM, Rieckmann KM, Edstein MD, 2006. Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects? Br J Clin Pharmacol 61: 682689.[Crossref]
    [Google Scholar]
  23. Seden K, Dickinson L, Khoo S, Back D, 2010. Grapefruit–drug interactions. Drugs 70: 23732407.[Crossref]
    [Google Scholar]
  24. Constantino L, Paixão P, Moreira R, Portela MJ, Do Rosario VE, Iley J, 1999. Metabolism of primaquine by liver homogenate fractions. Evidence for monoamine oxidase and cytochrome P450 involvement in the oxidative deamination of primaquine to carboxyprimaquine. Exp Toxicol Pathol 51: 299303.[Crossref]
    [Google Scholar]
  25. Frisher H, Meillovitz RL, Ahmad T, Nora MV, 1991. The conversion of primaquine to primaquine-aldehyde, primaquine-alcohol, and carboxyprimaquine, a major plasma metabolite. J Lab Clin Med 117: 468476.
    [Google Scholar]
  26. Ganesan S, Tekwani BL, Sahu R, Tripathi LM, Walker LA, 2009. Cytochrome P450-dependent toxic effects of primaquine on human erythrocytes. Toxicol Appl Pharmacol 241: 1422.[Crossref]
    [Google Scholar]
  27. FDA, 2006. Guidance for Industry Drug Interaction Studies—Study Design, Data Analysis, and Implications for Dosing and Labeling. Rockville, MD: FDA.
    [Google Scholar]
  28. Projean D, Baune B, Farinotti R, Flinois J, Beaune P, Taburet A, Ducharme J, 2003. In vitro metabolism of chloroquine: identification of Cyp2c8, Cyp3a4, and Cyp2d6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos 31: 748754.[Crossref]
    [Google Scholar]
  29. Huang Y, Okochi H, May B, Legname G, Prusiner SB, Benet LZ, Guglielmo BJ, Lin ET, 2006. Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by p-glycoprotein. Drug Metab Dispos 34: 11361144.[Crossref]
    [Google Scholar]
  30. Karamanakos PN, Trafalis DT, Geromichalos GD, Pappas P, Harkitis P, Konstandi M, Marselos M, 2009. Inhibition of rat hepatic CYP2E1 by quinacrine: molecular modeling investigation and effects on 4-(methyl nitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced mutagenicity. Arch Toxicol 83: 571580.[Crossref]
    [Google Scholar]
  31. Edwards G, Mcgrath CS, Ward SA, Supanaranond W, Pukrittayakamee S, Davis TME, White NJ, 1993. Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. Br J Clin Pharmacol 35: 193198.[Crossref]
    [Google Scholar]
  32. Brewer GJ, Tarlow AR, Kellermeyer RW, Alving AS, 1962. The hemolytic effect of primaquine. XV. Role of methemoglobin. J Lab Clin Med 59: 905916.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2011.11-0498
Loading
/content/journals/10.4269/ajtmh.2011.11-0498
Loading

Data & Media loading...

  • Received : 01 Aug 2011
  • Accepted : 13 Sep 2011
  • Published online : 01 Dec 2011
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error